Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters
New Strategy Head Will Seek Higher Earning Innovation
Apr 06 2022
•
By
Andrew McConaghie
Novartis is the leader in number of new approvals in recent years - but does not have a big-earning blockbuster like Trulicity or Keytruda to power its US sales. • Source: Alamy
More from Business
More from Scrip